Cargando…

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK

Patients with Nucleophosmin (NPM)- Anaplastic Lymphoma Kinase (ALK) fusion positive Anaplastic Large Cell Lymphoma produce autoantibodies against ALK indicative of an immune response against epitopes of the chimeric fusion protein. We asked whether ALK-expression in other malignancies induces specif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Damm-Welk, Christine, Siddiqi, Faraz, Fischer, Matthias, Hero, Barbara, Narayanan, Vignesh, Camidge, David Ross, Harris, Michael, Burke, Amos, Lehrnbecher, Thomas, Pulford, Karen, Oschlies, Ilske, Siebert, Reiner, Turner, Suzanne, Woessmann, Wilhelm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2016
Materias:	Short Research Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964121/ https://www.ncbi.nlm.nih.gov/pubmed/27471553 http://dx.doi.org/10.7150/jca.15238

Ejemplares similares

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
por: Singh, Vijay Kumar, et al.
Publicado: (2019)

Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma
por: Damm-Welk, Christine, et al.
Publicado: (2020)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
por: Stadler, Serena, et al.
Publicado: (2018)

Characterization and diagnostic application of genomic NPM-ALK fusion sequences in anaplastic large-cell lymphoma
por: Krumbholz, Manuela, et al.
Publicado: (2018)

Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas
por: Cerchietti, Leandro, et al.
Publicado: (2011)

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis
por: McDuff, Fiona Kate Elizabeth, et al.
Publicado: (2011)

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
por: Haque, Moinul, et al.
Publicado: (2019)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
por: Kreutmair, Stefanie, et al.
Publicado: (2022)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

TrkA is a binding partner of NPM‐ALK that promotes the survival of ALK (+) T‐cell lymphoma
por: Shi, Wenyu, et al.
Publicado: (2017)

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2019)

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
por: Zdzalik, Daria, et al.
Publicado: (2014)

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2023)

SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein()
por: Vishwamitra, Deeksha, et al.
Publicado: (2015)

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
por: Lobello, Cosimo, et al.
Publicado: (2018)

Inhibition of Rac controls NPM–ALK-dependent lymphoma development and dissemination
por: Colomba, A, et al.
Publicado: (2011)

NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target
por: Andraos, Elissa, et al.
Publicado: (2021)

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015)

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL
por: Hare, Lucy, et al.
Publicado: (2021)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
por: George, Suraj Konnath, et al.
Publicado: (2014)

NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases
por: Pearson, Joel D., et al.
Publicado: (2012)

Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK–driven lymphomagenesis
por: Redl, Elisa, et al.
Publicado: (2020)

The role of Alk-1 and Alk-5 in the mechanosensing of chondrocytes
por: Sanz-Ramos, Patricia, et al.
Publicado: (2014)

ALK in Neuroblastoma: Biological and Therapeutic Implications
por: Trigg, Ricky M., et al.
Publicado: (2018)

BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL
por: Garland, Gavin D., et al.
Publicado: (2021)

De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells
por: Babin, Loélia, et al.
Publicado: (2022)

Atractylodin Inhibits Interleukin-6 by Blocking NPM-ALK Activation and MAPKs in HMC-1
por: Chae, Hee-Sung, et al.
Publicado: (2016)

Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials?
por: Damm-Welk, Christine, et al.
Publicado: (2022)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

Proteomic Phosphosite Analysis Identified Crucial NPM-ALK-Mediated NIPA Serine and Threonine Residues
por: Gengenbacher, Anina, et al.
Publicado: (2019)

Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK
por: Uchihara, Yuki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_00qhsrirfpjorpj8up6dq8dtbk